ClinicalTrials.gg
CompletedNCT00436111Updated Feb 16, 2007

Characterization of Macroprolactinemia

An observational study in Hyperprolactinemia, sponsored by Kansai Medical University. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2007-02-16.

Sponsored by Kansai Medical University · Observational

Study type
Observational
Model
Defined population
Time perspective
Retrospective
Sex
All
01

Study summary

The purpose of this study is to clarify the nature of macroprolactin which has recently been highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia. The results of this study are beneficial for the patients to whom unnecessary medications and unnecessary radiological examinations have been performed.

We used the remained serum samples taken for routine prolactin determination during the past several years. Since the blood was basically taken to examine the causes of hyperprolactinemia and only remained serum samples were used for this study, the Ethics Committee of Kobe City General Hospital judged that it was not required to obtain approval number.

02

Conditions studied

  • Hyperprolactinemia

Browse trials for

Keywords

  • hyperprolactinemia
  • autoantibody
03

In context

Hyperprolactinemia

39 studies on the registry are indexed under Hyperprolactinemia; 4 are open to participants now.

Browse Hyperprolactinemia studies →

Lead sponsor

Kansai Medical University is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Eligibility criteria

Inclusion Criteria:

  • Clinical diagnosis of hyperprolactinemia
05

Study design

Observational model
Defined population
Time perspective
Retrospective
06

Study locations

1 site
  • Kansai Medical University
    Osaka, 570-8506, Japan
07

References and documents

Publications

  • Hattori N, Nakayama Y, Kitagawa K, Ishihara T, Saiki Y, Inagaki C. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol. 2006 Aug;190(2):287-93. doi: 10.1677/joe.1.06871. PubMed 16899562 ↗
  • Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab. 2005 May;90(5):3036-44. doi: 10.1210/jc.2004-1600. Epub 2005 Feb 1. PubMed 15687336 ↗
  • Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab. 1997 Sep;82(9):3107-10. doi: 10.1210/jcem.82.9.4250. PubMed 9284753 ↗
  • Hattori N, Ishihara T, Ikekubo K, Moridera K, Hino M, Kurahachi H. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9. doi: 10.1210/jcem.75.5.1430082. PubMed 1430082 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2007
First posted
Feb 16, 2007
Start
Jan 2005
Completion
Dec 2006
Last update
Feb 16, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 16, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00436111
Lead sponsor
Kansai Medical University
First posted
Feb 16, 2007
Start date
Jan 2005
Completion
Dec 2006
Last update
Feb 16, 2007

Study contacts

Naoki Hattori, M.D., Ph.D.
study chair · Department of Pharmacology, Kansai Medical University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion